Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.

Purpose Sarcoidosis frequently is complicated by small nerve fiber loss (SNFL), which can be quantified using corneal confocal microscopy (CCM). Prior studies suggest that the innate repair receptor agonist cibinetide reverses corneal nerve loss. This phase 2b, 28-day, randomized trial of 64 subjects with sarcoid-associated SNFL and neuropathic pain assessed the effect of cibinetide on corneal nerve fiber area (CNFA) and regenerating intraepidermal fibers (GAP-43+) as surrogate endpoints for disease modification, pain severity, and functional capacity (6-minute walk test [6MWT]). Methods Cibinetide (1, 4, or 8 mg/day) was compared to placebo. The primary study endpoint was a change in CNFA at 28 days. Results The placebo-corrected mean change from baseline CNFA (μm2) at day 28 was 109 (95% confidence interval [CI], -429, 647), 697 (159, 1236; P = 0.012), and 431 (-130, 992) in the 1, 4, and 8 mg groups, respectively. Intraepidermal GAP-43+ fibers increased in the 4 mg group (P = 0.035). Further, changes in CNFA correlated with changes in GAP-43+ (ρ = 0.575; P = 0.025) and 6MWT (ρ = 0.645; P = 0.009). Pain improved significantly in all groups, with subjects having moderate-severe pain reporting a clinically meaningful placebo-corrected decrease in pain intensity in the 4 mg group (P = 0.157). Conclusions Cibinetide significantly increased small nerve fiber abundance in the cornea and skin, consistent with a disease modifying effect. The relationships between CNFA and other clinical measures of disease support its use as a surrogate endpoint to assess potential disease modifying therapies for neuropathy.

[1]  Mohammad A. Dabbah,et al.  An Automatic Tool for Quantification of Nerve Fibers in Corneal Confocal Microscopy Images , 2017, IEEE Transactions on Biomedical Engineering.

[2]  N. Pritchard,et al.  Risk Factors Associated With Corneal Nerve Alteration in Type 1 Diabetes in the Absence of Neuropathy: A Longitudinal In Vivo Corneal Confocal Microscopy Study , 2016, Cornea.

[3]  P. Hauer,et al.  The Diagnostic Performance and Clinical Relevance of Corneal Confocal Microscopy (CCM) in Patients with Diabetic Peripheral Neuropathy (S44.001) , 2016 .

[4]  J. Arezzo,et al.  Long-Acting C-Peptide and Neuropathy in Type 1 Diabetes: A 12-Month Clinical Trial , 2016, Diabetes Care.

[5]  Mengyuan Zhang,et al.  ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception , 2016, Peptides.

[6]  G. Bennett,et al.  Increasing placebo responses over time in U.S. clinical trials of neuropathic pain , 2015, Pain.

[7]  R. Malik,et al.  Corneal Confocal Microscopy Detects Small Fibre Neuropathy in Patients with Upper Gastrointestinal Cancer and Nerve Regeneration in Chemotherapy Induced Peripheral Neuropathy , 2015, PloS one.

[8]  Elise M. Halpern,et al.  In vivo corneal confocal microscopy and prediction of future-incident neuropathy in type 1 diabetes: a preliminary longitudinal analysis. , 2015, Canadian journal of diabetes.

[9]  C. Thiemermann,et al.  Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. , 2015, Pharmacology & therapeutics.

[10]  G. Lauria,et al.  Side and time variability of intraepidermal nerve fiber density , 2015, Neurology.

[11]  Minshan Jiang,et al.  Corneal confocal microscopy for assessment of diabetic peripheral neuropathy: a meta-analysis , 2015, British Journal of Ophthalmology.

[12]  Nathan Efron,et al.  Corneal Confocal Microscopy Predicts 4-Year Incident Peripheral Neuropathy in Type 1 Diabetes , 2015, Diabetes Care.

[13]  Nathan Efron,et al.  Fully Automated, Semiautomated, and Manual Morphometric Analysis of Corneal Subbasal Nerve Plexus in Individuals With and Without Diabetes , 2014, Cornea.

[14]  X. Navarro,et al.  Assessment of sensory thresholds and nociceptive fiber growth after sciatic nerve injury reveals the differential contribution of collateral reinnervation and nerve regeneration to neuropathic pain , 2014, Experimental Neurology.

[15]  K. Kirsh,et al.  The chronic pain patient and functional assessment: use of the 6-Minute Walk Test in a multidisciplinary pain clinic , 2014, Current medical research and opinion.

[16]  A. Dahan,et al.  ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response , 2014, Molecular pain.

[17]  A. Dahan,et al.  Corneal nerve quantification predicts the severity of symptoms in sarcoidosis patients with painful neuropathy , 2013 .

[18]  A. Dahan,et al.  ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density , 2013, Molecular Medicine.

[19]  Mitra Tavakoli,et al.  Corneal Confocal Microscopy to Assess Diabetic Neuropathy: An Eye on the Foot , 2013, Journal of diabetes science and technology.

[20]  Liang Xu,et al.  Corneal nerve structure and function in patients with non-sjogren dry eye: clinical correlations. , 2013, Investigative ophthalmology & visual science.

[21]  A. Boulton,et al.  Corneal Nerve Loss Detected With Corneal Confocal Microscopy Is Symmetrical and Related to the Severity of Diabetic Polyneuropathy , 2013, Diabetes Care.

[22]  I. Merkies Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial , 2013, Neurology.

[23]  P. Ghezzi,et al.  The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model , 2013, Neuroscience.

[24]  Nathan Efron,et al.  Corneal Confocal Microscopy Detects Early Nerve Regeneration in Diabetic Neuropathy After Simultaneous Pancreas and Kidney Transplantation , 2012, Diabetes.

[25]  A. Dahan,et al.  Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study , 2012, Molecular medicine.

[26]  Michael A. Yamin,et al.  Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita ) diabetic mouse sympathetic ganglia , 2011, Experimental Neurology.

[27]  A. Dahan,et al.  ARA290, a Peptide Derived from the Tertiary Structure of Erythropoietin, Produces Long-term Relief of Neuropathic Pain: An Experimental Study in Rats and &bgr;-Common Receptor Knockout Mice , 2011, Anesthesiology.

[28]  R. Freeman,et al.  Efficacy and Safety of Antioxidant Treatment With α-Lipoic Acid Over 4 Years in Diabetic Polyneuropathy , 2011, Diabetes Care.

[29]  D. Moller,et al.  Sarcoidosis—scientific progress and clinical challenges , 2011, Nature Reviews Rheumatology.

[30]  C. Schmitz,et al.  Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study , 2010, Journal of the peripheral nervous system : JPNS.

[31]  J. Valls-Solé,et al.  European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Fe‐deration of Neurological Societies and the Peripheral Nerve Society , 2010, European journal of neurology.

[32]  C. Sommer,et al.  Elevated proinflammatory cytokine expression in affected skin in small fiber neuropathy , 2010, Neurology.

[33]  G. Lauria,et al.  Intraepidermal nerve fiber density and its application in sarcoidosis , 2009, Neurology.

[34]  J. Tavee,et al.  Small fiber neuropathy: A burning problem , 2009, Cleveland Clinic Journal of Medicine.

[35]  Michael A. Yamin,et al.  Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin , 2008, Proceedings of the National Academy of Sciences.

[36]  D. Patel,et al.  In vivo laser scanning confocal microscopy confirms that the human corneal sub-basal nerve plexus is a highly dynamic structure. , 2008, Investigative ophthalmology & visual science.

[37]  Nathan Efron,et al.  Surrogate Markers of Small Fiber Damage in Human Diabetic Neuropathy , 2007, Diabetes.

[38]  J. Denny Molecular mechanisms, biological actions, and neuropharmacology of the growth-associated protein GAP-43. , 2006, Current neuropharmacology.

[39]  Peter R Eastwood,et al.  Six minute walk distance in healthy subjects aged 55-75 years. , 2006, Respiratory medicine.

[40]  G. V. van Heck,et al.  Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). , 2004, British journal of health psychology.

[41]  Jacques Fermanian,et al.  Development and validation of the Neuropathic Pain Symptom Inventory , 2004, Pain.

[42]  N. Efron,et al.  Morphology of corneal nerves in soft contact lens wear. A comparative study using confocal microscopy. , 2003, Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians.

[43]  Justin C McArthur,et al.  Epidermal reinnervation after intracutaneous axotomy in man , 2003, The Journal of comparative neurology.

[44]  Sanjay V. Patel,et al.  Confocal microscopy in vivo in corneas of long-term contact lens wearers. , 2002, Investigative ophthalmology & visual science.

[45]  G. Hunninghake,et al.  ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. , 1999, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[46]  Albert Dahan,et al.  ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes , 2015, Molecular medicine.

[47]  J. de Vries,et al.  The small fiber neuropathy screening list: Construction and cross-validation in sarcoidosis. , 2011, Respiratory medicine.

[48]  ATS statement: guidelines for the six-minute walk test. , 2002, American journal of respiratory and critical care medicine.